Morepen Laboratories has secured a multi-year Contract Development and Manufacturing Organization (CDMO) mandate valued at approximately Rs 825 crore (USD 91 million) from a leading global pharma major.

Supplies under the mandate are expected to commence within the next 4–5 months, with execution scheduled through Q1 of the following financial year, subject to customary operational and regulatory processes.